{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:49:25Z","timestamp":1787899765107,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.03.029","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:03:27Z","timestamp":1774425807000},"page":"879.e1-879.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Superior Chronic Graft-versus-Host Disease\u2013Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus\/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1895-0325","authenticated-orcid":false,"given":"Alfonso","family":"Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0731","authenticated-orcid":false,"given":"Quenton Rashawn","family":"Bubb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9786-3010","authenticated-orcid":false,"given":"Hrishikesh K.","family":"Srinagesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0818-0084","authenticated-orcid":false,"given":"Ryan","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-853X","authenticated-orcid":false,"given":"Everett","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7698-5934","authenticated-orcid":false,"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Negrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Shizuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1912-4076","authenticated-orcid":false,"given":"Vanessa","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2026.03.029_bib0001","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/hematology.2022000352","article-title":"Allogeneic transplantation for advanced acute leukemia","volume":"2022","author":"Weisdorf","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.029_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/bmt.2008.1","article-title":"Allogeneic transplantation for ALL in adults","volume":"41","author":"Stein","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.029_bib0003","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11899-015-0265-2","article-title":"Quality of life in the chronic GVHD consortium cohort: lessons learned and the long road ahead","volume":"10","author":"Krupski","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.029_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.beha.2008.02.011","article-title":"Impact of graft-versus-host disease on survival","volume":"21","author":"Pasquini","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.029_bib0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12185-024-03813-0","article-title":"Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort","volume":"120","author":"Ohwada","year":"2024","journal-title":"Int J Hematol"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.029_bib0006","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3324\/haematol.2016.149294","article-title":"A prospective randomized trial comparing cyclosporine\/methotrexate and tacrolimus\/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"T\u00f6rl\u00e9n","year":"2016","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.jtct.2026.03.029_bib0007","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/bloodadvances.2023010310","article-title":"Tacrolimus\/methotrexate vs tacrolimus\/reduced-dose methotrexate\/mycophenolate for graft-versus-host disease prevention","volume":"7","author":"Hamilton","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.029_bib0008","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2026.03.029_bib0009","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.03.029_bib0010","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.029_bib0011","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.029_bib0012","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1093\/ajhp\/zxae239","article-title":"Clinical review of substitutions or alternatives for critical chemotherapy drug shortages in hematologic malignancies","volume":"82","author":"Tinajero","year":"2025","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.029_bib0013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.029_bib0014","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.029_bib0015","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/bjh.18765","article-title":"Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission","volume":"201","author":"Nagler","year":"2023","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2026.03.029_bib0016","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s41409-025-02716-w","article-title":"Beneficial effect of PTCy and a short duration of immune suppression on relapse risk in acute myeloid leukemia patients with pretransplant MRD","volume":"60","author":"Morsink","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.029_bib0017","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/ajh.70059","article-title":"Risk of relapse post reduced intensity conditioning allogeneic stem cell transplant in patients with high-risk myeloid neoplasms based on GvHD prophylaxis: PTCy vs TAC\/MTX","volume":"100","author":"Hassan","year":"2025","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.029_bib0018","doi-asserted-by":"crossref","first-page":"208.e1","DOI":"10.1016\/j.jtct.2022.12.017","article-title":"Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national marrow donor program-sponsored prospective clinical trial","volume":"29","author":"Shaw","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.03.029_bib0019","first-page":"3277","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","author":"Shaffer","year":"20244228","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.029_bib0020","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.029_bib0021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.029_bib0022","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00277-025-06199-z","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin in haploidentical stem cell transplantation: a systematic review and meta-analysis","volume":"104","author":"Jin","year":"2025","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.029_bib0023","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.029_bib0024","doi-asserted-by":"crossref","first-page":"576.e1","DOI":"10.1016\/j.jtct.2023.06.008","article-title":"Phase II study of myeloablative 7-8\/8-matched allotransplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil","volume":"29","author":"El Jurdi","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:57:59Z","timestamp":1782745079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672600237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S266663672600237X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.029","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Superior Chronic Graft-versus-Host Disease\u2013Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus\/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}